Publications Archive - Page 25 of 50

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Cascone, T., William, W. N., Jr, Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M., Carter, B. W., Federico, L., Reuben, A., Khan, M., Dejima, H., Francisco-Cruz, A., Parra, E. R., Solis, L. M., Fujimoto, J., Tran, H. T., Kalhor, N., Fossella, F. V., Mott, F. E., … Sepesi, B. (2021). Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature medicine, 27(3), 504–514. https://doi.org/10.1038/s41591-020-01224-2

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Read More »

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Guest Account

van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M., Zweegman, S., Breij, E., Roemer, M., & Mutis, T. (2021). Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood cancer journal, 11(2), 38. https://doi.org/10.1038/s41408-021-00430-6

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment Read More »

Decoding neuronal composition and ontogeny of individual hypothalamic nuclei

Guest Account

Ma, T., Wong, S., Lee, B., Ming, G. L., & Song, H. (2021). Decoding neuronal composition and ontogeny of individual hypothalamic nuclei. Neuron, 109(7), 1150–1167.e6. https://doi.org/10.1016/j.neuron.2021.01.026

Decoding neuronal composition and ontogeny of individual hypothalamic nuclei Read More »

ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases

Guest Account

Pouzol, L., Baumlin, N., Sassi, A., Tunis, M., Marrie, J., Vezzali, E., Farine, H., Mentzel, U., & Martinic, M. M. (2021). ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21431. https://doi.org/10.1096/fj.202002465R

ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases Read More »

Intratumoral Plasmid IL12 Expands CD8 + T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy

Guest Account

Telli, M. L., Nagata, H., Wapnir, I., Acharya, C. R., Zablotsky, K., Fox, B. A., … & Crosby, E. J. (2021). Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy. Clinical Cancer Research, 27(9), 2481-2493.

Intratumoral Plasmid IL12 Expands CD8 + T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy Read More »

Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer

Guest Account

Marwitz, S., Ballesteros-Merino, C., Jensen, S. M., Reck, M., Kugler, C., Perner, S., Drömann, D., Goldmann, T., & Fox, B. A. (2021). Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. Journal for immunotherapy of cancer, 9(2), e001469. https://doi.org/10.1136/jitc-2020-001469

Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer Read More »

Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness

Guest Account

Ning, J., Ye, Y., Bu, D., Zhao, G., Song, T., Liu, P., Yu, W., Wang, H., Li, H., Ren, X., Ying, G., Zhao, Y., & Yu, J. (2021). Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness. Molecular therapy : the journal of the American Society of Gene Therapy, 29(6), 2067–2087. https://doi.org/10.1016/j.ymthe.2021.02.016

Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness Read More »

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort

Guest Account

Machado-Rugolo, J., Gutierrez Prieto, T., Fabro, A. T., Parra Cuentas, E. R., Sá, V. K., Baldavira, C. M., Rainho, C. A., Castelli, E. C., Farhat, C., Takagaki, T. Y., Nagai, M. A., & Capelozzi, V. L. (2021). Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. Pharmacogenomics and personalized medicine, 14, 239–252. https://doi.org/10.2147/PGPM.S286717

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort Read More »

Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence

Guest Account

Mori, H., Bolen, J., Schuetter, L., Massion, P., Hoyt, C. C., VandenBerg, S., Esserman, L., Borowsky, A. D., & Campbell, M. J. (2020). Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence. Journal of mammary gland biology and neoplasia, 25(4), 417–432. https://doi.org/10.1007/s10911-021-09479-2

Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence Read More »

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling

Guest Account

López-Janeiro, Á., Ruz-Caracuel, I., Ramón-Patino, J. L., De Los Ríos, V., Villalba Esparza, M., Berjón, A., Yébenes, L., Hernández, A., Masetto, I., Kadioglu, E., Goubert, V., Heredia-Soto, V., Barderas, R., Casal, J. I., de Andrea, C. E., Redondo, A., Mendiola, M., Peláez-García, A., & Hardisson, D. (2021). Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Cancers, 13(4), 794. https://doi.org/10.3390/cancers13040794

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling Read More »

Publications

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Decoding neuronal composition and ontogeny of individual hypothalamic nuclei

ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases

Intratumoral Plasmid IL12 Expands CD8 + T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy

Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer

Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort

Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling

Follow Us

More Links

Stay Connected